ADORA2A and prostate carcinoma: Among these targets, five of them (A2AR/ADORA2A, CSK, CYP24A1, BRDT, and BRAF) have been suggested in recent scientific papers to be related to prostate cancer and all can interact with ligands with known therapeutic advantages against advanced prostate cancer.